Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery
Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows a Significant Reduction in Deep Vein Thrombosis and PulmonaryEmbolism Compared with Enoxaparin with Similarly Low BleedingRates GENEVA, July 8, 2007 - Late-breaking Phase III clinical trialdata presented today at the XXI International Society on Thrombosisand Haemostasis (ISTH) Congress demonstrate that once-daily...
Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery
GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase IIIclinical trial data presented today at the XXI InternationalSociety on Thrombosis and Haemostasis (ISTH) Congress demonstratethat once-daily rivaroxaban achieved superior efficacy in theprevention of venous thromboembolism (VTE) in patients undergoingknee replacement surgery in a head-to-head comparison withenoxaparin, the curren...
Cipralex demonstrates superiority to duloxetine for acute treatment
of depression in new study
COPENHAGEN, June 4, 2007-A new study published today in thejournal Current Medical Research and Opinion showed thatCipralex® (escitalopram) was superior to Cymbalta®(duloxetine) in the acute treatment of patients with majordepressive disorder (MDD) and was at least as efficacious inlong-term treatment. The study directly compared Cipralex® (anallosteric serotonin reuptake inh...
Newly Published Data Demonstrates Superiority of Cipralex Over
Duloxetine for Acute Treatment of Depression
- Cipralex Better Tolerated and at Least as Effective inLong-Term Treatment H. Lundbeck A/S announces new study data published today in thejournal Current Medical Research and Opinion, demonstrating thatCipralex(R) (escitalopram) was superior to duloxetine in the acutetreatment of patients with major depressive disorder (MDD)...
The Lancet Publishes PREVAIL Study Results Showing Lovenox
Superiority Over Unfractionated Heparin for Reducing the Risk of
Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
Risk of Having a Venous ThromboEmbolism (VTE) is Reduced by aSignificant 43% in Acute Ischemic Stroke Patients Treated WithClexane(R) / Lovenox(R) BRIDGEWATER, N.J., April 20, 2007 /PRNewswire-FirstCall/ --Sanofi-aventis announced the publication of the PREVAIL (Preventionof VTE after Acute Ischemic Stroke with LMWH Enoxaparin) trial inthe April 21st issue of The Lancet. The results of th...